ArticleThe Journal of veterinary medical science2025
Oxypeucedanin alleviates cisplatin-induced intestinal toxicity through impairing caspase-3/gasdermin E signaling.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxypeucedanin (OPD) is a compound naturally present in plants such as Peucedanum praeruptorum, a kind of medicinal herb which displays anti-inflammatory activities. However, its protective role on chemotherapy-induced inflammatory injuries has not been well studied. In the present study, we found that OPD could alleviate cisplatin (CDDP)-induced intestinal inflammatory injury in mice, which was accompanied by the decrease of immune cell infiltration and reverse of mitochondrial dysfunction in intestinal tissue. Then we noticed that OPD could inhibit cisplatin-induced intestinal cell pyroptosis, which was indicated by the reduction of LDH release and PI positive signal in the cells and tissues. The reason is that OPD could suppress caspase-3/gasdermin E (GSDME) signaling, which is a critical mediator of chemotherapy-induced tissue injury. We also detected the upstream factors of caspase-3/GSDME signaling and have found that cisplatin-induced Reactive oxygen species (ROS) production and DNA damages could also be inhibited by OPD. Importantly, OPD administration did not reverse cisplatin-suppressed tumor burden in animals. Our present study provides a potential application of OPD to reduce cisplatin-induced side effects, without interfering the anti-tumor capacity, indicating a way to extend the duration of cisplatin administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.